We may very well see a repeat of this situation in the next couple days when the FDA considers a different Advisory Committee's recommendation on the Covid vacc

We may very well see a repeat of this situation in the next couple days when the FDA considers a different Advisory Committee's recommendation on the Covid vaccine boosters. There is speculation that the FDA may ignore the recommendation to limit boosters to 65+ and those with risk of severe disease and instead approve it for a broader population. At the end of the day, the Advisory Committee is just that - a committee that advises and the FDA is not bound by that recommendation. It seems a bit disingenuous of the committee members to expect the broader FDA to just rubber stamp their recommendation, particularly when it was a split decision.